



JAMEEL FUND FOR INFECTIOUS DISEASE  
RESEARCH AND INNOVATION [ROUND-1]

KING ABDULAZIZ UNIVERSITY LED  
AWARD ONLY

DEANSHIP OF SCIENTIFIC AFFAIRS

KING ABDULAZIZ UNIVERTSITY

## مجتمع جميل السعودية توحد جهودها مع جامعة الملك عبدالعزيز لمكافحة فيروسات كورونا والأمراض التي تسببها

- بدعم من مجتمع جميل السعودية، صندوق جميل لأبحاث الأمراض المعدية والابتكار في السعودية يقدم الدعم لعدد من المشاريع البحثية.
- مجتمع جميل توقع إتفاقيات مع جامعة الملك عبدالعزيز في مجالات دعم الأبحاث العلمية والتعاون في المجالات الأكاديمية والتطويرية المختلفة

جدة، المملكة العربية السعودية، 12 إبريل 2021: أعلنت مجتمع جميل السعودية وجامعة الملك عبد العزيز عن إطلاق صندوق جميل لأبحاث الأمراض المعدية والابتكار في السعودية وذلك لمكافحة فيروس كورونا المستجد والأمراض التي تسببها مثل هذه الفيروسات، بما في ذلك وباء فيروس كورونا الشرق الأوسط (MERS). ويأتي هذا التعاون لتسريع تطوير الحلول السريرية لمعالجة مجموعة من الأمراض المعدية المنتشرة في منطقة الخليج وعلى مستوى العالم.

وسيقدم صندوق جميل الدعم لعدد من المشاريع البحثية مؤثرا يعزز قدرتنا على فهم ومنع وتشخيص وعلاج فيروسات كورونا والأمراض المعدية الأخرى. وإلى جانب الحلول العملية، سيتم إصدار مقالات كنتيجة للأبحاث تتم مراجعتها من قبل الباحثين في المجال ونشرها مجانًا. كما سيشرف على صندوق جميل لأبحاث الأمراض المعدية والابتكار في السعودية، لجنة مشتركة تضم ممثلين من جامعة الملك عبد العزيز وامبريال كوليدج لندن. وسيدعم هذا الصندوق الباحثين السعوديين من خلال عدة مراحل. وتطلق المرحلة الأولى، في 2021، من خلال دعم مشاريع الباحثين في جامعة الملك عبد العزيز.

وبهذه المناسبة صرح معالي الأستاذ الدكتور عبد الرحمن بن عبيد اليوبي، رئيس جامعة الملك عبد العزيز بقوله: "تأتي هذه الاتفاقية ضمن الأهداف الاستراتيجية للجامعة للمساهمة في تطوير بيئة محفزة وداعمة للإبداع والابتكار، وتحسين المشاركة المجتمعية لمنسوبي الجامعة وتقديم إسهامات مميزة لخدمة المجتمع. نشكر مجتمع جميل السعودية على ثقفتهم في الجامعات والباحثين السعوديين للمساهمة في مكافحة مجموعة من التحديات الصحية الملحة في منطقة الخليج وعلى مستوى العالم."

وتعليقا على الاتفاقية، صرح حسن جميل، نائب رئيس مجلس إدارة مجتمع جميل: "تأتي هذه الاتفاقية ضمن سلسلة الجهود الواسعة التي تبذلها مجتمع جميل السعودية في تنمية المهارات والتزامها بدعم الأبحاث العلمية وتمكين المجتمع السعودي والعلماء من فرص الابتكار لمستقبل أفضل، إلى جانب تعزيز العلاقة بين مجتمع جميل السعودية وجامعة الملك عبد العزيز وشركائها من المؤسسات الدولية مثل امبريال كوليدج لندن من خلال العديد من البرامج التي تهدف إلى فتح آفاق بحثية جديدة يكون لها أثر عميق في تمكين العلماء والباحثين السعوديين من إيجاد سبل جديدة لمعالجة بعض التحديات الصحية الملحة في المملكة."

ومن باب حرص مجتمع جميل السعودية على تحقيق مجتمع صحي آمن وقعت المؤسسة مؤخرا عدة اتفاقيات تعاون مع جامعة الملك عبد العزيز بهدف دعم الأبحاث العلمية في مجال الأمراض المعدية والتعاون في المجالات الأكاديمية والتطويرية المختلفة وذلك في إطار تعزيز الجهود وتبادل الخبرات وإستثمار الإمكانيات المشتركة لخدمة المجتمع. وتهدف الإتفاقيات إلى بناء شراكة إستراتيجية لدعم الأبحاث في مجال الأمراض المعدية والإبتكار، ودعم الباحثين السعوديين في الجامعة، وتشجيع التعاون مع الجهات البحثية من داخل المملكة وخارجها لتعزيز جودة الأبحاث العلمية

### مجتمع جميل السعودية

مجتمع جميل السعودية، مؤسسة أهلية تأسست عام 2010 م في السعودية وتهدف إلى تنمية المجتمع من خلال خمسة محاور رئيسية تشمل تنمية المهارات، الاهتمام بصحة المجتمع، تمكين رواد الأعمال، تعزيز دور المرأة، والمبادرات الإنسانية. تلتقي هذه المحاور لتحقيق هدف إستراتيجي هو السعي نحو مستقبل أفضل من خلال المساعدة في توفير فرص عمل مناسبة لشباب وشابات الوطن والتي بدورها تساهم في إيجاد سبل جديدة لتوفير حياة أفضل لأفراد المجتمع والحفاظ على ازدهار الاقتصاد في مختلف الصناعات.

تحتفل مجتمع جميل السعودية وعائلة جميل حاليا بثلاثة أرباع قرن من الزمان على مزاولة الأنشطة الخيرية. نوثق هذه المسيرة من خلال مشروع 75 عام / 75 صوت/ 75 حكاية الذي يضم شهادات من شركائنا ومسانديننا.

## **Community Jameel Saudi joins hands with King Abdulaziz University (KAU) to help combat Coronaviruses and related diseases**

- Backed by the Community Jameel Saudi, the Jameel Fund for Infectious Disease Research and Innovation will provide funding to several research projects.
- Community Jameel Saudi signs agreements with King Abdulaziz University to promote scientific research and cooperation in various academic and development fields

Jeddah, Saudi Arabia, April 20, 2021: Community Jameel Saudi and King Abdulaziz University (KAU ) announced the launch of the Jameel Fund for Infectious Disease Research and Innovation (Jameel Fund) in Saudi Arabia to combat COVID-19 and related diseases, including the Middle East respiratory syndrome (MERS). The collaboration aims to accelerate the development of clinical solutions to treat a range of infectious diseases in the Gulf region and worldwide.

The Jameel Fund targets several high-impact projects that advance our ability to understand, prevent, diagnose, and treat coronaviruses and other infectious diseases. Alongside practical solutions, research articles to be produced out of the collaboration will be reviewed by specialist researchers before they are made available and published for free by both sides. The Jameel Fund for Infectious Disease Research and Innovation will also be supervised by a joint committee comprising representatives from KAU and counterparts from Imperial College London. The fund will support Saudi researchers through many phases, the first of which will be launched in 2021 by supporting the projects of researchers in King Abdulaziz University.

His Excellency Prof. Dr. Abdul Rahman bin Obaid Al-Youbi, President of KAU, said: "This agreement is part of the strategic goals of KAU to contribute to developing an environment that stimulates and supports creativity and innovation. KAU also shares the same interest with Community Jameel Saudi for serving the community through remarkable contributions. We thank Community Jameel Saudi for their confidence in the ability of Saudi universities and researchers to combat a set of pressing health challenges in the Gulf region and world."

Hassan Jameel, Vice-Chairman of Community Jameel, said: "This agreement builds on the broad efforts made by the Community Jameel Saudi in developing skills and its commitment to support scientific research and empowering Saudi community and scientists by providing innovation opportunities for a better future. It also aims to strengthen the relationship between the Community Jameel Saudi and KAU and its partners from international institutions such as Imperial College through many programmes that aim to open new research horizons that have a profound impact on enabling Saudi scientists and researchers to find new ways to respond to some urgent health challenges in the Kingdom."

Out of its keenness to create a safe and healthy society, Community Jameel Saudi recently signed several cooperation agreements with King Abdulaziz University to support scientific research focusing on infectious diseases, and also to promote collaboration in various academic and development fields. The agreements also aim to support Saudi researchers at KAU and encourage cooperation with research bodies from inside and outside Saudi Arabia to enhance the quality of scientific research.

### About Community Jameel

Established in 2010, Community Jameel Saudi is a foundation aims at supporting and enriching the Saudi communities through five development areas: competency development, women empowerment, community well-being, entrepreneur's advancement, and humanitarian initiatives. These five areas of development share a primary goal: to act as a catalyst to create job opportunities that lead to better lives, thereby keeping the economy thriving across various industries.

Community Jameel Saudi and the Jameel family are currently celebrating three quarters of a century of philanthropy; this journey is marked through the 75 Years / 75 Voices / 75 Stories project, which includes contributions from our partners and constituents.

## JAMEEL FUND FOR INFECTIOUS DISEASE RESEARCH AND INNOVATION

### Round 1: The Transmission and Pathogenesis of Coronaviruses, including Covid-19, SARS, and MERS.

**Award Type: King Abdulaziz University (KAU) led research award only**

**[KAU P.Is grant applications through KAU system-max \$50,000 for entire project period]**

Call for proposals	<b>20<sup>th</sup> April 2021</b>
Deadline for submission	<b>19<sup>th</sup> May 2021</b>
Announcement of approved projects	<b>28<sup>th</sup> June 2021</b>
Starting date of accepted proposal	<b>2<sup>nd</sup> August 2021</b>
Duration of project	<b>12 months</b>

*\*Only those proposals will be considered that fulfil the terms and conditions at the end of this form*

*\*Email your proposal as PDF to [Dsr-research@kau.edu.sa](mailto:Dsr-research@kau.edu.sa)*

Field	Additional info/comments
Project Title	
Principal investigator details:	
Email address:	Area of expertise / specialization:
Please select your Faculty:	
Departmental affiliation:	
Research Centre or Unit affiliation:	
Co-Investigators and Department ( <i>Collaborators from KAU or non-KAU must provide details of their affiliations</i> ).	
Project Partners, collaborators at KAU and Imperial ( <i>optional</i> )	
Amount Requested	
Case for Support: Please upload your 2-page PDF which outlines:	-A description of the activities to be funded, including clear objectives and milestones. -Any preliminary data

	<p>-A statement of the expected deliverables and how these will meet the current need.</p>
<p>Attach your collaboration statement in case you have non-KAU collaborator or Imperial partners (1 page) to include:</p>	<p>-A clear description of the collaboration, why the project needs to be done collaboratively and the expected outcomes and impact. -Details of the research complementarity and how the partnership will benefit both institutes.</p>
<p>Attach one extra page in total for:</p>	<p>-Justification of available resources -A statement that you have consulted with relevant clinical or academic teams and that they have the capacity to undertake the project if you intend to use clinical and/or virological samples -Confirmation that a Safety Risk Assessment has been completed and approved by the Safety Department (<i>see attached form</i>) – to help departments review safety issues and put in place suitable controls. See terms and conditions at the end of this form. -You should also highlight that you have the relevant ethical permissions (<i>preliminary at least at the time of submission</i>). -On award a data management plan and IP statement will be required, please confirm that this can be provided.</p>
<p>Upload a Safety Risk Assessment Form signed by the relevant Safety Team at KAU.</p>	
<p>Attach a letter from the host Head of Department or research centre.</p>	<p>-Supporting the proposal -Approving costs -Confirming the necessary facilities required are available to you.</p>
<p>For applications that involve Imperial's Enterprise team, please provide a Letter of Support. Other letters of support from partners/stakeholders are not mandatory but if available are encouraged to be included (<i>optional</i>).</p>	
<p>Has this proposal been applied elsewhere for funding? If yes, then please list details of the funding body here:</p>	

**The KAU P.I will be required to submit the following to DSR at KAU ([Dsr-research@kau.edu.sa](mailto:Dsr-research@kau.edu.sa)):**

- A progress report after six months.
- A comprehensive technical report after the completion period i.e. 12 months.
- A complete financial report including invoices after the completion.
- One Q1 publication with approved authors and collaborators
- P.Is must use their first affiliation as King Abdulaziz University, Saudi Arabia throughout.
- Acknowledgment statement must be added in all publications as well as reports with reference to King Abdulaziz University, Saudi Arabia, Imperial (wherever applicable) and Community Jameel.

**Terms and conditions:**

The call is open to applications from academic and honorary clinical staff at King Abdulaziz University.

Applicants should be in a position to start the project as soon as funding is agreed. No new staff should be recruited but costs are allowed for existing staff. Only direct research costs are eligible, indirect and estates costs are not permissible. Awards will be distributed internally based on 100% direct costs but excluding estates and infrastructure technicians, investigator time, and other indirect costs. Costs can include small items of equipment of up to equivalent \$13000 but larger capital items cannot be included. In case of partner from Imperial, their cost can be included and should be clearly laid out in your costings.

SARS-CoV-2 is a highly hazardous pathogen, and as such, any research work with the virus or with samples known to contain the virus, must be conducted in a containment level 3 (CL3) laboratory.

In light of the unprecedented and exceptional circumstances posed by SARS-CoV-2, certain diagnostics activities can be undertaken within a Micro Biological Safety Cabinet (MSC) at containment level 2 (CL2).

In order to clarify safety containment level requirements, below is a list of activities that must be conducted within a CL3 laboratory and diagnostics activities that, subject to risk assessment, may be conducted within a CL2 laboratory. Please consider the aspects below and the laboratory space you have access to when planning your COVID-19 research projects.

**1. Work to be conducted at CL3**

The following work must be conducted at CL3:

- Any work with samples for confirmation of known or presumptive positives of SARS-CoV-2
- Any propagation, culturing or deliberate work on SARS-CoV-2
- Any research work with samples that contain, or are likely to contain, SARS-CoV-2.



**Note** that the exceptions in containment agreed only apply to diagnostics laboratories. Since viable virus cannot be isolated from blood samples, work may be conducted at CL2 using universal precautions, following a suitable risk assessment.

## 2. Work that may be conducted within an MSC at CL2 (diagnostics laboratories only)

Following completion of a suitable and sufficient risk assessment, the following work with samples potentially containing SARS-CoV-2 may be conducted within an MSC at CL2:

- Preparation of specimens for molecular testing (for example respiratory virus PCR) prior to sample inactivation.
- Division, aliquoting, or diluting of respiratory tract specimens, faecal specimens, urine specimens, and tissue specimens in which the virus has not been inactivated.

**Note** that waste routes for disposal of samples and/or contaminated material must be appropriate for such highly hazardous organisms.

General safety precautions such as training, access control, spill and emergency procedures must be defined and form part of the risk assessment.